Fewer doctor visits mean weaker earnings for device makers and hospital chains

Featured Story

Fewer doctor visits mean weaker earnings for device makers and hospital chains

April 22, 2013 1:09 am by | 1 Comments

In the past week, medical testing companies, such as Quest Diagnostics, medical device makers Johnson & Johnson and Abbott Laboratories, hospital operators, such as HCA Holdings Inc, and even diaper maker Kimberly-Clark, which has a surgical supply unit, have cited a slowdown in use of medical services.


Teva’s generics push its Q1 earnings one penny over forecast

Teva’s generics push its Q1 earnings one penny over forecast

May 1, 2014 7:22 am by | 0 Comments

TEL AVIV (Reuters) – Teva Pharmaceutical Industries reported on Thursday higher first-quarter earnings that beat analysts’ estimates by one cent due in part to the launch of several generic products in the United States.
Teva, the world’s largest gener…


Lilly reports a disappointing Q1 with 16% drop in revenue

Lilly reports a disappointing Q1 with 16% drop in revenue

April 24, 2014 7:06 am by | 0 Comments

(Reuters) – Eli Lilly and Co reported lower-than-expected quarterly revenue on Thursday, hurt by disappointing sales of its cancer and diabetes drugs, and its shares fell more than 3 percent.
Indianapolis-based Lilly, which is trying to regain its foo…



Gambro purchase puts a dent in Baxter’s third-quarter earnings

Gambro purchase puts a dent in Baxter’s third-quarter earnings

October 17, 2013 7:22 am by | 0 Comments

(Reuters) – Medical products maker Baxter International Inc reported a 7 percent fall in third-quarter earnings, hurt by charges related to its $4 billion acquisition of Swedish dialysis products company Gambro AB.
Net earnings fell to $544 million, or…


Medicare, Medicaid enrollees give slight boost to UnitedHealth’s third-quarter profit

Medicare, Medicaid enrollees give slight boost to UnitedHealth’s third-quarter profit

October 17, 2013 6:17 am by | 0 Comments

(Reuters) – UnitedHealth Group Inc said on Thursday that its third-quarter profit rose about 1 percent, helped by the enrollment of an additional 275,000 people in its health insurance plans.
The company, the largest U.S. health insurer, reported earni…


Increased sales and profits on the horizon for Roche

Increased sales and profits on the horizon for Roche

October 17, 2013 1:40 am by | 0 Comments

ZURICH (Reuters) – Swiss drugmaker Roche Holding AG confirmed its forecast of rising sales and profit for this year as it posted an 8 percent rise in third-quarter sales helped by growing momentum of its new breast cancer drugs.
The world’s largest mak…


Sales rise for Actelion, 2013 earnings forecast confirmed

Sales rise for Actelion, 2013 earnings forecast confirmed

October 17, 2013 1:38 am by | 0 Comments

ZURICH (Reuters) – Actelion, Europe’s largest biotech company, confirmed its full-year outlook on Thursday ahead of a widely anticipated approval of its big drug hope Opsumit by U.S. health regulators later this week.
Nine month sales of its main produ…


Increased sales for J&J, but more set aside for legal issues

Increased sales for J&J, but more set aside for legal issues

October 16, 2013 12:36 pm by | 0 Comments

The shifting landscape of American health care — for good or bad, depending on your opinion, status, employer, and particular changes — was evident Tuesday when one of the Philadelphia region’s larger private employers, Johnson & Johnson, reporte…



Cost-cutting, low taxes help Abbott beat forecasts

Cost-cutting, low taxes help Abbott beat forecasts

October 16, 2013 8:07 am by | 0 Comments

Oct 16 (Reuters) – Abbott Laboratories reported better than expected quarterly earnings despite disrupted sales of its infant formulas in China, helped by cost cuts and lower taxes.
The company, which spun off its branded prescription drugs business in…


Rite Aid quarterly profits boosted by generic drug sales

Rite Aid quarterly profits boosted by generic drug sales

September 23, 2013 8:00 am by | 0 Comments

(Reuters) – Rite Aid Corp, the No. 3 drugstore chain in the United States, reported a surprise quarterly profit after generic drug sales boosted margins, sending its shares up by a fifth to their highest in more than five years.
Like rivals Walgreen C…


Nordion reports huge jump in Q3 profit with after-tax gain from sale of targeted therapies business

Nordion reports huge jump in Q3 profit with after-tax gain from sale of targeted therapies business

September 5, 2013 7:54 am by | 0 Comments

(Reuters) – Canada’s Nordion Inc, a provider of isotopes used in medical imaging, reported a huge jump in third-quarter profit after recording an after-tax gain of about $182 million on the sale of its targeted therapies business.
Net profit rose to $1…


Shares drop for Regeneron as eye drug sales slow in second quarter

Shares drop for Regeneron as eye drug sales slow in second quarter

August 7, 2013 2:31 am by | 0 Comments

(Reuters) – The explosive growth in the sales of Regeneron Pharmaceuticals Inc’s Eylea eye drug slowed in the second quarter as existing patients moved to less-frequent dosing.
Shares of Regeneron fell 6.1 percent on Tuesday even though the company sa…


Declining generic drug sales hit Teva as second-quarter profit falls

Declining generic drug sales hit Teva as second-quarter profit falls

August 1, 2013 5:30 pm by | 0 Comments

JERUSALEM (Reuters) – Teva Pharmaceutical Industries reported lower underlying quarterly profit on Thursday, hurt by a decline in generic drug sales in the United States and Europe.
Teva, the world’s largest generic drugmaker, earned $1.20 per share ex…


Cardinal Health beats market estimates with adjusted quarterly profit

Cardinal Health beats market estimates with adjusted quarterly profit

August 1, 2013 8:04 am by | 0 Comments

(Reuters) – Cardinal Health Inc reported an adjusted quarterly profit that beat market estimates due to margin expansion in its wholesale drug and medical supply businesses.
The Dublin, Ohio-based company forecast earnings, excluding one-time items, of…


Second-quarter earnings rose, but Mylan expects 2013 revenue to be on low end of expectations

Second-quarter earnings rose, but Mylan expects 2013 revenue to be on low end of expectations

August 1, 2013 8:04 am by | 0 Comments

Aug 1 (Reuters) – Generic drugmaker Mylan Inc said on Thursday that its second-quarter earnings rose, but forecast 2013 revenue would be at the low end of an expected $7 billion to $7.4 billion range because of the weakening of India’s and Japan’s curr…


Cigna’s second-quarter profit rose on low medical costs, increased revenue

Cigna’s second-quarter profit rose on low medical costs, increased revenue

August 1, 2013 6:14 am by | 0 Comments

(Reuters) – Cigna Corp said on Thursday that second-quarter profit rose as medical costs were low and revenue increased from health insurance, supplemental benefit plans like dental and vision, and disability and life insurance.
The company reported ne…